I do not interpret today's press release from $IFRX positively. 
1) I am sceptical about the IXPLORE study (IFX-1 in AAV). 
2) The cooperation with $MRK probably only consists of Merck contributing Keytruda for free.
3) The endpoints in the #COVID19 study are strangely selected.